Abstract | BACKGROUND: METHODS: A total of 265 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study, with no known cardiovascular disease, underwent CIMT measurement at baseline and at 5 years. RESULTS: In all, 129 men and 136 women, aged 54.6±12.3 years, were studied. Median CIMT at baseline was 0.63 mm (interquartile range 0.52-0.73 mm) and increased to 0.67 mm (0.56-0.78 mm) after 5 years (P<0.001). CIMT increment correlated with baseline adiponectin, age, and smoking (all P<0.05) and baseline CIMT (P<0.001), but not with sex, fasting glucose, lipid profiles, hypertension, or diabetes. In multiple linear regression analysis, baseline serum adiponectin level was an independent predictor of CIMT increment β (standardized beta)=-0.17, P=0.015], after adjusting for age, smoking, baseline CIMT, hypertension, body mass index, fasting glucose, low-density lipoprotein cholesterol, and triglycerides. CONCLUSION:
|
Authors | Elaine Hui, Aimin Xu, Wing-Sun Chow, Paul C H Lee, Carol H Y Fong, Stephen C W Cheung, Hung Fat Tse, Ming-Tak Chau, Bernard M Y Cheung, Karen S L Lam |
Journal | Metabolic syndrome and related disorders
(Metab Syndr Relat Disord)
Vol. 12
Issue 10
Pg. 517-22
(Dec 2014)
ISSN: 1557-8518 [Electronic] United States |
PMID | 25211296
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ADIPOQ protein, human
- Adiponectin
- Biomarkers
|
Topics |
- Adiponectin
(blood, deficiency)
- Adult
- Aged
- Biomarkers
(blood)
- Carotid Artery Diseases
(blood, diagnostic imaging, epidemiology)
- Carotid Intima-Media Thickness
- Disease Progression
- Down-Regulation
- Female
- Hong Kong
(epidemiology)
- Humans
- Male
- Metabolism, Inborn Errors
(blood, diagnosis, epidemiology)
- Middle Aged
- Predictive Value of Tests
- Prevalence
- Prospective Studies
- Risk Factors
- Time Factors
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|